Emergent BioSolutions (EBS) Change in Account Payables (2010 - 2026)

Emergent BioSolutions' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$14.4 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 166.67% year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$17.4 million (up 51.67% YoY), while the FY2025 annual figure was -$8.4 million, up 74.55% from the prior year.
• Change in Account Payables was -$14.4 million for Q1 2026 at Emergent BioSolutions, down from $11.4 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $31.0 million in Q1 2023 to a low of -$23.0 million in Q3 2024.
• Historically, Change in Account Payables has averaged -$3.5 million across 5 years, with a median of -$4.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables surged 310.88% in 2023, then slumped 500.0% in 2025.
• A 5-year view of Change in Account Payables shows it stood at -$2.2 million in 2022, then tumbled by 222.73% to -$7.1 million in 2023, then slumped by 43.66% to -$10.2 million in 2024, then soared by 211.76% to $11.4 million in 2025, then tumbled by 226.32% to -$14.4 million in 2026.
• The last three Change in Account Payables figures came in at -$14.4 million (Q1 2026), $11.4 million (Q4 2025), and -$4.0 million (Q3 2025), per Business Quant data.